The interview highlights the transformational impact of PSMA PET-CT imaging in prostate cancer, emphasizing how advanced imaging is shifting prevalent patient populations. It also explores the evolving treatment paradigm in earlier stages of the disease and how these changes are influencing treatment approaches for mCRPC.

This interview was conducted on Feb 10, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.